Colchicine delivered by a novel nanoparticle platform alleviates atherosclerosis by targeted inhibition of NF-κB/NLRP3 pathways in inflammatory endothelial cells
Open Access
- 30 November 2023
- journal article
- research article
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 21 (1) , 1-23
Abstract
Atherosclerosis, a chronic inflammatory disease characterized by arterial plaque formation, is one of the most prominent causes of cardiovascular diseases. However, the current treatments often do not adequately compromise the chronic inflammation-mediated plaque accumulation and the disease progression. Therefore, a new and effective strategy that blocks atherosclerosis-associated inflammation is urgently needed to further reduce the risk. Colchicine, a potent anti-inflammatory medication, has shown great potential in the treatment of atherosclerosis, but its adverse effects have hampered its clinical application. Herein, we developed a novel delivery nanosystem encapsulated with colchicine (VHPK-PLGA@COL), which exhibited improved biosafety and sustained drug release along with the gradual degradation of PLGA and PEG as confirmed both in vitro and in vivo. Surface modification of the nanoparticles with the VHPK peptide ensured its capability to specifically target inflammatory endothelial cells and alleviate atherosclerotic plaque accumulation. In the ApoE − / − atherosclerotic mouse model, both colchicine and VHPK-PLGA@COL treatment significantly decreased the plaque area and enhanced plaque stability by blocking the NF-κB/NLRP3 pathways, while VHPK-PLGA@COL exhibited enhanced therapeutic effects due to its unique ability to target inflammatory endothelial cells without obvious long-term safety concerns. In summary, VHPK-PLGA@COL has the potential to overcome the key translational barriers of colchicine and open new avenues to repurpose this drug for anti-atherosclerotic therapy.Keywords
Funding Information
- 2023 Ziyang Medical Science Project (KY2023023)
- the General projects of Chongqing Natural Science Foundation (CSTB2023NSCQ-MSX0115)
- the Kuanren Talents Program of the second afliated hospital of Chongqing Medical University (202228)
- The National Natural Science Foundation of China (31871182)
- the Science and Technology Project Affiliated with the Science Department of Yuzhong District of Chongqing City (20210134)
This publication has 55 references indexed in Scilit:
- PEGylation as a strategy for improving nanoparticle-based drug and gene deliveryAdvanced Drug Delivery Reviews, 2016
- Colchicine in cardiovascular disease: an ancient drug with modern tricksHeart, 2016
- Endothelial Cell Dysfunction and the Pathobiology of AtherosclerosisCirculation Research, 2016
- 2015 ESC Guidelines for the diagnosis and management of pericardial diseasesEuropean Heart Journal, 2015
- PKC-β activation inhibits IL-18-binding protein causing endothelial dysfunction and diabetic atherosclerosisCardiovascular Research, 2015
- Construction and Evaluation of Fe3O4-Based PLGA Nanoparticles Carrying rtPA Used in the Detection of Thrombosis and in Targeted ThrombolysisACS Applied Materials & Interfaces, 2014
- Low-Dose Colchicine for Secondary Prevention of Cardiovascular DiseaseJACC, 2013
- Poly(lactide- co -glycolide) porous scaffolds for tissue engineering and regenerative medicineInterface Focus, 2012
- Noninvasive Vascular Cell Adhesion Molecule-1 Imaging Identifies Inflammatory Activation of Cells in AtherosclerosisCirculation, 2006
- Inflammation in atherosclerosisNature, 2002